BS_SB12W1XT
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 16.918528252299605
- age_years
- 2.518
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.597
- MYC_TARGETS_V1+0.496
- ANDROGEN_RESPONSE+0.444
- OXIDATIVE_PHOSPHORYLATION+0.437
- MYC_TARGETS_V2+0.436
- TGF_BETA_SIGNALING+0.433
- MTORC1_SIGNALING+0.420
- UNFOLDED_PROTEIN_RESPONSE+0.405
- CHOLESTEROL_HOMEOSTASIS+0.392
- ADIPOGENESIS+0.385
Top 10 suppressed
- KRAS_SIGNALING_DN-0.352
- PANCREAS_BETA_CELLS-0.254
- SPERMATOGENESIS-0.221
- MYOGENESIS-0.174
- ESTROGEN_RESPONSE_LATE-0.023
- BILE_ACID_METABOLISM+0.024
- APICAL_SURFACE+0.030
- XENOBIOTIC_METABOLISM+0.081
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.106
- HYPOXIA+0.118
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 1A9B5D3A-CEB0-4225-9C3D-CBE98A007A3A | — | — | 0.944 |
| 2 | ED604501-C110-4693-820B-DE9FB648FEAA | — | — | 0.936 |
| 3 | DC01D165-E257-49D6-8B9B-37CA7DE398F6 | — | — | 0.934 |
| 4 | A7C71CEF-A5C7-4BAC-9090-9808B029190B | — | — | 0.932 |
| 5 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.923 |
| 6 | E317AD4C-E877-499A-B108-2F39A40D1682 | — | — | 0.921 |
| 7 | 633064DB-D3ED-4B5F-B48F-6924AD719647 | — | — | 0.920 |
| 8 | A061C2FD-B726-422D-9470-43249B49F5BD | — | — | 0.918 |
| 9 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.917 |
| 10 | 2566FDAC-EF10-4996-8890-FA0BEC771676 | — | — | 0.916 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.597 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.496 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.444 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.437 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.436 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.433 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.420 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.405 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.392 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.385 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.381 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.374 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.362 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.361 | Inavolisib | — uncovered |
| APOPTOSIS | 0.347 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.294 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.294 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.291 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.283 | Inavolisib | — uncovered |
| PEROXISOME | 0.277 | Idelalisib | — uncovered |